rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

HUTCHMED (China) Limited - American Depositary Shares

HCM · Nasdaq

Health CareBiotechnologyAbove a falling average

HCM stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 10.2% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
54 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders54+4 on the quarter
New · exited9 · 5
Reported value$50.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SCHRODER INVESTMENT MANAGEMENT GROUPunchanged · filed 13 Aug 20261,477,494$15.8M00.0%
Allianz Asset Management GmbHunchanged · filed 14 Aug 2026837,475$12.5M00.0%
STATE STREET CORPadded · filed 7 Aug 2026313,611$3.4M+8,782+2.9%
AIA Group Ltdunchanged · filed 31 Jul 2026291,229$3.1M00.0%
M&G PLCreduced · filed 6 Aug 2026242,791$2.7M-12,677−5.0%
Amundireduced · filed 11 Aug 2026204,385$2.2M-27,861−12.0%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026194,472$2.1M+117,958+154.2%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026130,200$1.4M-1,862−1.4%
BNP PARIBAS FINANCIAL MARKETSreduced · filed 13 Aug 2026104,425$1.1M-2,079−2.0%
XY Capital Ltdadded · filed 11 Aug 2026104,130$1.1M+55,736+115.2%
31 Mar 2023 – 30 Jun 2026
475562Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Charles George Rupert Nixon Company insiderGroup General Counsel · last 20 May 20260 · 0
Chig Fung Cheng Company insiderActing CEO and CFO · last 20 May 20260 · 0
Lorenso Chiu Company insiderDeputy Chief Financial Officer · last 20 May 20260 · 0
Wei-guo Su Company insiderCEO and CSO · last 20 May 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202538.7%
Operating profit marginFY 2025 · to 31 Dec 2025-7.1%
Free cash flow marginFY 2025 · to 31 Dec 2025-14.4%
Return on capital employedFY 2025 · to 31 Dec 2025-2.7%
Cash conversionFY 2025 · to 31 Dec 2025-14.2%
Debt to equityFY 2025 · to 31 Dec 20250.10×
Research spendFY 2025 · to 31 Dec 202527.0%
Revenue growthFY 2025 · to 31 Dec 2025-13.0%
Earnings per share growthFY 2024 · to 31 Dec 2024-66.7%
Share count trendFY 2025 · to 31 Dec 20250.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$71.3M
Free cash flowFY 2025 · to 31 Dec 2025−$78.8M

Analyst forecasts

No analyst forecasts yet.